Warburg Pincus to take significant minority stake in specialty diagnostics firm Sebia

Warburg Pincus is set to acquire a significant minority stake in Sebia, a global provider of specialty diagnostics, in a deal expected to close no earlier than the first quarter of 2026. Terms of the transaction have not been disclosed. 

Sebia, founded in 1967 and headquartered in Lisses, France, develops in vitro diagnostics systems used to screen and monitor a range of complex conditions. The company supplies instruments and reagents used in oncology – particularly multiple myeloma – as well as diabetes, haemoglobinopathies, autoimmune and infectious diseases, and other rare disorders. It serves customers in more than 140 countries and maintains its US headquarters in Norcross, Georgia. 

Warburg Pincus, a global private equity firm focused on growth investing, has entered exclusive negotiations to acquire the stake from existing shareholders. CVC Funds, La Caisse (formerly CDPQ) and Téthys Invest will remain significant investors following completion, with Sebia continuing to operate as an independent company. 

Execution of the deal remains subject to applicable employee consultation processes and customary regulatory approvals. According to the parties, closing is not expected before the first quarter of 2026.

Sebia has built a strong position in clinical protein electrophoresis and related diagnostic technologies, providing labs with platforms that translate subtle changes in proteins and biomarkers into interpretable diagnostic information for clinicians. The company has expanded its portfolio in recent years through acquisitions in autoimmunity and infectious disease testing, broadening its menu beyond oncology and metabolic disorders. 

Management frames the partnership as an opportunity to accelerate growth while preserving a focus on scientific rigour and product quality. Sebia’s chief executive Jean-Marc Chermette has said the company’s mission is to provide “powerful tools” that convert what is happening in a patient’s body into a readable language for clinicians, and that Warburg Pincus’ healthcare experience and growth orientation will support the next phase of that strategy. 

Warburg Pincus, which has more than $80bn in assets under management and a long track record in healthcare investing, described Sebia as a “best-in-class diagnostics platform” with differentiated technology and a strong history of innovation for customers worldwide. The firm plans to back further advances in diagnostic modalities, scientific capabilities and manufacturing scale. 

Specialty diagnostics continues to attract investor interest as health systems and life sciences companies look to improve early detection, disease monitoring and patient stratification in oncology and chronic conditions. Platforms like Sebia’s, which combine proprietary reagents, instruments and software, are increasingly seen as critical infrastructure for laboratories managing complex testing workloads.

While neither Sebia nor Warburg Pincus has commented publicly on valuation, media reports suggest the transaction could involve more than 30 per cent of the company’s shares and value the business at around €5.5bn. 

Following completion, Sebia will continue to operate from its base in France with its existing investor group and Warburg Pincus supporting its global expansion and diagnostic innovation agenda.